Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma. Many of our trials are developed by our own team, who have identified needs or opportunities based on caring for patients or findings from our lab research. These investigator-initiated trials offer patients access to new and emerging therapeutics before they are available elsewhere. We offer trials for initial treatment as well as for relapsed disease with a focus on improving outcomes and limiting side effects.
Featured Clinical Trials
Newly-Diagnosed Mantle Cell Lymphoma
24-654: BRAZAN Trial in Frontline Mantle Cell Lymphoma
Principal Investigator: Christine Ryan, MD
This trial explores a novel approach to treating mantle cell lymphoma by integrating targeted agents into standard induction and maintenance therapies. Patients receive zanubrutinib, a BTK inhibitor, during both phases and may also receive sonrotoclax, a BCL2 inhibitor, during maintenance. These are oral medicines that target survival pathways of the mantle cell lymphoma cells.
21-040: AVO in Previously Untreated Mantle Cell Lymphoma
Principal Investigator: Austin Kim, MD
This trial enrolls patients with mantle cell lymphoma and a TP53 genetic mutation who require initial treatment. Patients receive treatment with three targeted drugs: acalabrutinib, a BTK inhibitor; venetoclax, a BCL2 inhibitor; and obinutuzumab, a type of immunotherapy. Acalabrutinib and venetoclax are oral medicines that target survival pathways of the mantle cell lymphoma cells. Obinutuzumab is administered by infusion into the vein.
Relapsed/Refractory Mantle Cell Lymphoma
24-104: Glofitamab and Lenalidomide in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Principal Investigator: Christine Ryan, MD
This trial combines bispecific antibody therapy—a form of immunotherapy—with standard care treatment for patients with relapsed or refractory mantle cell lymphoma. Patients receive glofitamab, a bispecific antibody, and lenalidomide. Our goal is that the combination of these two drugs will work well to achieve disease remission.
25-264: Zanubrutinib With or Without Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator: Christine Ryan, MD
Zanubrutinib is a standard treatment option for relapsed/refractory mantle cell lymphoma. However, zanubrutinib does not always work well for every patient, and it can stop working well to treat the mantle cell lymphoma after a certain period of time. The purpose of this study is to test if a new study drug called sonrotoclax in combination with zanubrutinib is safe and if it works better in patients with relapsed/refractory mantle cell lymphoma compared to zanubrutinib alone. Zanubrutinib and sonrotoclax are oral medicines that target survival pathways of the mantle cell lymphoma cells.
21-124: Anti-CD20/CD19 CAR T-cell therapy in Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator: Caron Jacobson, MD
This trial investigates the safety and efficacy of MB-CART2019.1, which is a CAR T-cell therapy derived from immune system cells, known as T cells, collected from a patient's blood. CAR T-cells are genetically engineered to express a receptor that may help them recognize and bind to cancer cells. After the T-cells are activated, they can then attack the cancer cells to which they are bound. The currently approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma are engineered to recognize only one marker on the lymphoma cells. This trial investigates a new CAR T-cell therapy that is engineered to recognize two markers on the lymphoma cells.
Mantle Cell Lymphoma Clinical Trials
877-338-7425
Search Clinical Trials
Ongoing Research in Mantle Cell Lymphoma
Our research is guided by correlative science. This approach involves analyzing patient samples like tumor tissue, blood, and other body fluids collected before, during, and after treatment. This analysis generates data we use to try to understand why therapies have varying effects and how they impact cancer at a close-up level. These efforts help identify markers to predict treatment success, personalize care, and advance future cancer therapies. Our current focus areas in the lab include:
- Developing tests to help match patients with the treatments from which they are most likely to benefit
- Minimally invasive genetic analyses to characterize lymphoma biology and predict treatment response (cell-free DNA sequencing)
- Developing functional tests that predict patient treatment outcomes based on the sensitivity of lymphoma cells from blood, bone marrow, or tissue biopsies when exposed to drugs in reproducible experimental conditions in the laboratory (BH3 profiling, single-cell biophysical profiling)
- Demonstrating how the immune system contributes to disease behavior and drug sensitivity and how it can be utilized by novel treatments to improve patient outcomes
- Characterizing the rare lymphoma cells that remain in the body of patients whose lymphoma is not detectable by standard laboratory and imaging studies and identifying novel therapeutic targets of these residual cancer cells. Such studies could guide future clinical trial efforts to prolong remissions and, ideally, convert remissions into cures